Migration is associated with baseline severity and progress over time in autism spectrum disorder: Evidence from a French prospective longitudinal study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 26 01 2021
accepted: 22 07 2022
entrez: 6 10 2022
pubmed: 7 10 2022
medline: 12 10 2022
Statut: epublish

Résumé

The prevalence of autism-spectrum disorder (ASD) has been shown to be higher in migrant families, but it is also a challenge for health care professionals to offer adequate services to families that face multiple challenges. In the context of the EPIGRAM study (a French prospective, multisite, longitudinal observational study implementing integrative care practices (ICPs) for children with ASD), we aimed to assess the impact of migration on children with ASD. 89 children with ASD aged 3 to 6 years old (92% males) were recruited and followed up for 12 months. The children were clinically assessed using several instruments. At baseline, children had severe autism on average on the Children Autism Rating Scale (CARS, mean = 44; SD = 6.51) and moderate autism on the PsychoEducational profile-3-R (PEP-3-R) maladaptive behavior category (mean = 30; SD = 29.89). Thirty percent of the families had a low socio-economic status, and 56% were first-generation immigrants. For all clinical variables, children of immigrant parents had more severe autism and developmental delays at baseline. A linear mixed model established an improvement in all clinical characteristics over the 12 months of the study. This trend may be attributed to ICPs or any naturally occurring event during that period. Families shared this positive view over time. However, the improvements were slower for two clinical dimensions of the PEP-3-R in children from migrant families. For the inappropriate behavior category, the time effect diminished by an average of 0.83 percentile/month for children whose parents were migrants vs. children whose parents were non-migrants. Similarly, for verbal behavior characteristics, the time effect diminished by an average of 1.32 percentile/month for children whose parents were migrants vs. children whose parents were non-migrants. Despite an overall positive improvement, we found that migration is associated baseline severity and progress over time in children with ASD. There is an urgent need to target the migrant population with specific research and understand the avenues that carry such higher severity. Study registration on clinicaltrials.gov under the number NCT02154828.

Sections du résumé

BACKGROUND
The prevalence of autism-spectrum disorder (ASD) has been shown to be higher in migrant families, but it is also a challenge for health care professionals to offer adequate services to families that face multiple challenges. In the context of the EPIGRAM study (a French prospective, multisite, longitudinal observational study implementing integrative care practices (ICPs) for children with ASD), we aimed to assess the impact of migration on children with ASD.
METHOD AND FINDINGS
89 children with ASD aged 3 to 6 years old (92% males) were recruited and followed up for 12 months. The children were clinically assessed using several instruments. At baseline, children had severe autism on average on the Children Autism Rating Scale (CARS, mean = 44; SD = 6.51) and moderate autism on the PsychoEducational profile-3-R (PEP-3-R) maladaptive behavior category (mean = 30; SD = 29.89). Thirty percent of the families had a low socio-economic status, and 56% were first-generation immigrants. For all clinical variables, children of immigrant parents had more severe autism and developmental delays at baseline. A linear mixed model established an improvement in all clinical characteristics over the 12 months of the study. This trend may be attributed to ICPs or any naturally occurring event during that period. Families shared this positive view over time. However, the improvements were slower for two clinical dimensions of the PEP-3-R in children from migrant families. For the inappropriate behavior category, the time effect diminished by an average of 0.83 percentile/month for children whose parents were migrants vs. children whose parents were non-migrants. Similarly, for verbal behavior characteristics, the time effect diminished by an average of 1.32 percentile/month for children whose parents were migrants vs. children whose parents were non-migrants.
CONCLUSION
Despite an overall positive improvement, we found that migration is associated baseline severity and progress over time in children with ASD. There is an urgent need to target the migrant population with specific research and understand the avenues that carry such higher severity.
CLINICAL TRIAL REGISTRATION
Study registration on clinicaltrials.gov under the number NCT02154828.

Identifiants

pubmed: 36201564
doi: 10.1371/journal.pone.0272693
pii: PONE-D-21-01376
pmc: PMC9536617
doi:

Banques de données

ClinicalTrials.gov
['NCT02154828']

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0272693

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist in relation to the manuscript.

Références

Front Psychiatry. 2021 Mar 18;12:566368
pubmed: 33815159
Lancet. 2016 Nov 19;388(10059):2501-2509
pubmed: 27793431
PLoS One. 2015 Nov 05;10(11):e0141964
pubmed: 26540408
Handb Clin Neurol. 2020;174:301-321
pubmed: 32977887
Pediatrics. 2010 Jan;125(1):e17-23
pubmed: 19948568
Autism. 2016 Feb;20(2):233-49
pubmed: 25916866
Front Psychiatry. 2019 Jan 23;9:751
pubmed: 30733689
Curr Clin Pharmacol. 2014 Feb;9(1):17-26
pubmed: 24050743
J Autism Dev Disord. 2019 Feb;49(2):632-646
pubmed: 30203308
J Autism Dev Disord. 2013 May;43(5):1050-6
pubmed: 22965298
Autism Res. 2022 Mar;15(3):570-585
pubmed: 35040590
Brain Dev. 2003 Apr;25(3):166-72
pubmed: 12689694
Pediatrics. 2020 Jan;145(1):
pubmed: 31843864
Eur J Public Health. 2017 Feb 01;27(1):101-110
pubmed: 28013245
Psychother Psychosom. 2008;77(5):271-9
pubmed: 18560252
Res Dev Disabil. 2015 Mar;38:242-55
pubmed: 25575287
Behav Neurosci. 2013 Aug;127(4):487-97
pubmed: 23688137
J Am Acad Child Adolesc Psychiatry. 2013 Jul;52(7):679-88
pubmed: 23800481
J Autism Dev Disord. 2020 Feb;50(2):455-466
pubmed: 31664612
Autism Res. 2019 Dec;12(12):1845-1859
pubmed: 31373761
EClinicalMedicine. 2020 Sep 09;26:100537
pubmed: 33089127
Handb Clin Neurol. 2020;173:225-240
pubmed: 32958176
Pediatrics. 2012 Nov;130 Suppl 2:S191-7
pubmed: 23118251
Pediatrics. 2011 May;127(5):e1303-11
pubmed: 21464190
J Can Acad Child Adolesc Psychiatry. 2013 May;22(2):131-8
pubmed: 23667359
Psychol Bull. 2020 Jan;146(1):1-29
pubmed: 31763860
Clin Psychol Rev. 2013 Dec;33(8):940-53
pubmed: 23988454
BJPsych Open. 2020 Aug 18;6(5):e92
pubmed: 32807250

Auteurs

Carlotta Bettencourt (C)

Groupe Hospitalo-Universitaire Pitié-Salpêtrière, Institut des pathologies du Développement de l'Enfant et de l'AdoLescent (IDEAL), APHP. SU, Paris, France.
Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7222, Institut des Systèmes Intelligents et Robotiques, Sorbonne Université, Paris, France.

Nicole Garret-Gloanec (N)

Centre Nantais de Parentalité, 1 rue Marmontel, Centre Hospitalo-Universitaire, Nantes, France.

Hugues Pellerin (H)

Groupe Hospitalo-Universitaire Pitié-Salpêtrière, Institut des pathologies du Développement de l'Enfant et de l'AdoLescent (IDEAL), APHP. SU, Paris, France.

Morgane Péré (M)

Direction de la recherche, Plateforme de Méthodologie et Biostatistique, Centre Hospitalo-Universitaire de Nantes, Nantes, France.

Maria Squillante (M)

49 rue de Siam, 29200 Brest, France.

Fabienne Roos-Weil (F)

Centre Médico-Psychologique, Paris, France.

Léa Ferrand (L)

Direction de la Recherche-Département promotion, Centre Hospitalo-Universitaire de Nantes, Nantes, France.

Anne-Sophie Pernel (AS)

CESAME, Centre Roger Misès, Angers, France.

Gisèle Apter (G)

Groupe Hospitalier du Havre, Université de Rouen Normandie, Le Havre, France.

David Cohen (D)

Groupe Hospitalo-Universitaire Pitié-Salpêtrière, Institut des pathologies du Développement de l'Enfant et de l'AdoLescent (IDEAL), APHP. SU, Paris, France.
Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7222, Institut des Systèmes Intelligents et Robotiques, Sorbonne Université, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH